



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 211/42, 405/06, 401/12, 405/12, 405/14, A61K 31/445		A1	(11) International Publication Number: WO 97/30031
			(43) International Publication Date: 21 August 1997 (21.08.97)
(21) International Application Number: PCT/EP97/00584		(81) Designated States: AL, AM, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KG, KR, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 7 February 1997 (07.02.97)			
(30) Priority Data: 96200379.4 15 February 1996 (15.02.96) EP			
(34) Countries for which the regional or international application was filed: DE et al.			
(71) Applicant (for all designated States except US): JANSSEN PHARMACEUTICA N.V. [BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE).		Published With international search report.	
(72) Inventors; and (75) Inventors/Applicants (for US only): BOSMANS, Jean-Paul, R., M., A. [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). LOVE, Christopher, J. [GB/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). DECLEYN, Michel, A., J. [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). D'HAEN, Henri, E., F. [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE).			

(54) Title: ESTERS OF 3-HYDROXY-PIPERIDINEMETHANOL DERIVATIVES

(57) Abstract

The present invention of compounds of formula (I), a stereochemically isomeric form thereof, an N-oxide form thereof or a pharmaceutically acceptable acid addition salt thereof, R¹ is C₁₋₆alkyloxy, C₂₋₆alkenyloxy or C₂₋₆alkynyloxy; R² is hydrogen or C₁₋₆alkyloxy, or when taken together R¹ and R² may form a bivalent radical of formula wherein in said bivalent radicals one or two hydrogen atoms may be substituted with C₁₋₆alkyl; R³ is hydrogen or halo; R⁴ is hydrogen or C₁₋₆alkyl; L is C₃₋₆cycloalkyl, C₃₋₆cycloalkanone, C₂₋₆alkenyl optionally substituted with aryl, or L is a radical of formula -Alk-R⁵, Alk-X-R⁶, -Alk-Y-C(=O)-R⁸, or -Alk-Y-C(=O)-NR¹⁰R¹¹ wherein each Alk is C₁₋₁₂alkanediyl; and R⁵ is hydrogen, cyano, C₁₋₆alkylsultonylamino, C₃₋₆cycloalkyl, C₃₋₆cycloalkanone, aryl, di(aryl)methyl or a heterocyclic ringsystem; R⁶ is hydrogen, C₁₋₆alkyl, hydroxyC₁₋₆alkyl, C₁₋₆cycloalkyl, aryl or heterocyclic ringsystem; X is O, S, SO₂ or NR⁷; said R⁷ being hydrogen, C₁₋₆alkyl or aryl; R⁸ is hydrogen, C₁₋₆alkyl, C₃₋₆cycloalkyl, aryl, arylC₁₋₆alkyl, di(aryl)methyl, C₁₋₆alkyloxy or hydroxy; Y is NR⁹ or a direct bond; said R⁹ being hydrogen, C₁₋₆alkyl or aryl; R¹⁰ and R¹¹ each independently are hydrogen, C₁₋₆alkyl, C₃₋₆cycloalkyl, aryl or arylC₁₋₆alkyl, or R¹⁰ and R¹¹ combined with the nitrogen atom bearing R¹⁰ and R¹¹ may form a pyrrolidiny or piperidiny ring both being optionally substituted with C₁₋₆alkyl, amino or mono or di(C₁₋₆alkyl)amino, or said R¹⁰ and R¹¹ combined with the nitrogen bearing R¹⁰ and R¹¹ may form a piperaziny or 4-morpholinyl radical both being optionally substituted with C₁₋₆alkyl. Processes for preparing said products, formulations comprising said products and their use as a medicine are disclosed, in particular for treating conditions which are related to impairment of gastric emptying.

